全球注射用抗糖尿病药物市场：现况分析与预测（2023-2030）

Injectables Antidiabetic Drugs Market: Current Analysis and Forecast (2023-2030)

出版日期: 2024年04月01日 | 出版商:

UnivDatos Market Insights Pvt Ltd | 英文 134 Pages | 商品交期: 最快1-2个工作天内

价格

简介目录

2023 年至 2030 年，全球注射型抗糖尿病药物市场预计将以约 6.1% 的复合年增长率成长。注射用抗糖尿病药物市场是指专注于注射治疗糖尿病药物的製药产业部分。这些药物旨在透过增加胰岛素分泌、提高胰岛素敏感性或减少肝臟中葡萄糖的产生来帮助糖尿病患者调节血糖水平。由于久坐的生活方式、不健康的饮食和人口老化等因素，全球糖尿病盛行率不断上升，这是市场的主要驱动力。例如，根据世界卫生组织 (WHO) 的统计，全球约有 4.22 亿人患有糖尿病。大多数糖尿病患者生活在低收入和中等收入国家。药物传递技术的进步也带动了更方便、更有效的注射型抗糖尿病药物的开发。此外，肥胖是第二型糖尿病的主要危险因素，全球肥胖流行与糖尿病盛行率的增加相对应。随着对抗肥胖的斗争取得进展，用于糖尿病管理的注射抗糖尿病药物的使用也可能会增加。

依药物类型，市场分为胰岛素、胰淀素类似物和 GLP-1 激动剂。其中，胰岛素製剂预计将拥有较高的市场占有率，原因如下。全球第 1 型和第 2 型糖尿病盛行率持续上升，推动了对胰岛素产品的需求。随着越来越多的人被诊断出患有糖尿病，对胰岛素治疗以实现血糖控制和预防併发症的需求不断增加。先进的胰岛素输送设备（例如胰岛素笔）的出现正在提高给药的便利性和胰岛素治疗的依从性。此外，随着第 2 型糖尿病的进展，许多患者最终可能需要胰岛素治疗才能达到血糖目标。

根据分销管道，市场分为医院药房、零售药房和网路药房。特别是，预计在预测期内，医院药局类别注射抗糖尿病药物的采用率将很高。医疗保健变得越来越复杂，越来越多的患者需要专门护理，包括糖尿病等慢性病患者。医院药局在提供药品和製药服务以支持医院内病患照护方面发挥着重要作用。医疗技术的进步促使了包括糖尿病在内的各种疾病的新疗法和治疗方法的发展。医院药局具备储存、准备和分发这些专用药物的能力，有助于分销通路领域的成长。

为了更瞭解注射抗糖尿病药物产业的市场介绍，将市场分为北美（美国、加拿大和北美其他地区）、欧洲（德国、英国、法国、西班牙、义大利和欧洲其他地区）和亚太地区（中国、日本、印度、亚太地区其他地区），并根据其在世界其他地区的全球影响力进行分析。由于糖尿病盛行率不断上升、一般人群对注射抗糖尿病药物的认识不断提高以及生活方式的改变，北美注射型抗糖尿病药物市场预计将继续增长。例如，根据 CDC 的数据，2020 年，65 岁及以上的成年人中有 2,720 万人患有糖尿病前期，占该年龄层的 48.8%。预计 2022 年确诊糖尿病的总费用为 4,130 亿美元，其中直接医疗费用为 3,070 亿美元，糖尿病带来的间接费用为 1,060 亿美元。

市场上的主要参与者包括AstraZeneca、 Novartis AG、Johnson & Johnson、Merck & Co. Inc、 Pfizer、Sanofi、Eli lilly、Bristol-Myers Squibb、Oramed、Astellas Pharma Inc.。

The Injectables antidiabetic drugs market is expected to register a CAGR of approx. 6.1% over the period of 2023-2030. The injectable antidiabetic drug market refers to the segment of the pharmaceutical industry focused on medications administered via injection for the treatment of diabetes mellitus. These drugs are designed to help regulate blood sugar levels in individuals with diabetes by either increasing insulin production, improving insulin sensitivity, or reducing glucose production in the liver. The rising prevalence of diabetes worldwide, fueled by factors such as sedentary lifestyles, unhealthy diets, and aging populations, is a significant driver of the market. For instance, According to the World Health Organization (WHO), Approximately 422 million people across the globe have diabetes. The majority of individuals with diabetes reside in low- and middle-income countries. Moreover, Advances in drug delivery technologies have led to the development of more convenient and effective injectable antidiabetic drugs. Furthermore, obesity is a major risk factor for type 2 diabetes, and the global obesity epidemic has led to a corresponding increase in diabetes prevalence. As efforts to address obesity continue, there may be an associated increase in the use of injectable antidiabetic drugs to manage diabetes..

Based on the Drug Type, the market has been categorized into insulin, amylin analogs, glp-1 agonists. Among them, the insulin segment is expected to grow at a higher share in the market due to The global prevalence of diabetes, both type 1 and type 2, continues to rise, driving the demand for insulin. As more people are diagnosed with diabetes, there is a growing need for insulin therapy to achieve glycemic control and prevent complications. The availability of advanced insulin delivery devices, such as insulin pens, has enhanced the ease of administration and adherence to insulin therapy. Moreover, With the progression of type 2 diabetes, many patients may eventually require insulin therapy to achieve glycemic targets.

Based on the distribution channel, the market has been categorized into hospital pharmacies, retail pharmacies, online pharmacies. Among them, the hospital pharmacies category is to witness higher adoption of Injectable Antidiabetic Drug during the forecast period. Healthcare is becoming increasingly complex, with a growing number of patients requiring specialized care, including those with chronic conditions such as diabetes. Hospital pharmacies play a crucial role in providing medications and pharmaceutical services to support patient care within the hospital setting. Advances in medical technology have led to the development of new treatments and therapies for various conditions, including diabetes. Hospital pharmacies are equipped to handle the storage, preparation, and dispensing of these specialized medications, contributing to their growth in the distribution channel segment.

For a better understanding of the market adoption of the Injectables antidiabetic drugs industry, the market is analyzed based on its worldwide presence in the countries such as North America (U.S., Canada, and Rest of North America), Europe (Germany, U.K., France, Spain, Italy, Rest of Europe), Asia-Pacific (China, Japan, India, Rest of Asia-Pacific), Rest of World. The North America injectable antidiabetic drug market is expected to continue to grow in the coming years, driven by the increasing prevalence of diabetes and growing awareness of injectable antidiabetic drug among the general population, change in lifestyle. For instance, in 2020, according to CDC, Among adults aged 65 years or older, 27.2 million had prediabetes, which corresponds to 48.8% of this age group. the estimated total cost of diagnosed diabetes in 2022 was $413 billion, $307 billion in direct medical costs, $106 billion in indirect costs attributable to diabetes.

Some of the major players operating in the market include AstraZeneca, Novartis AG, Johnson & Johnson, Merck & Co. Inc, Pfizer, Sanofi, Eli lilly, Bristol-Myers Squibb, Oramed, Astellas Pharma Inc.

1MARKET INTRODUCTION

1.1.Market Definitions
1.2.Main Objective
1.3.Stakeholders
1.4.Limitation

2RESEARCH METHODOLOGY OR ASSUMPTION

2.1.Research Process of the Injectables Antidiabetic Drugs Market
2.2.Research Methodology of the Injectables Antidiabetic Drugs Market
2.4.Respondent Profile

3MARKET SYNOPSIS

4EXECUTIVE SUMMARY

5IMPACT OF COVID-19 ON THE INJECTABLES ANTIDIABETIC DRUGS MARKET

6GLOBAL INJECTABLES ANTIDIABETIC DRUGS MARKET REVENUE, 2020-2030F

7MARKET INSIGHTS BY DRUG TYPE

7.1.Insulin
7.2.Amylin analogs
7.3.GLP-1 agonists

8MARKET INSIGHTS BY DISTRIBUTION CHANNEL

8.1.Hospital Pharmacies
8.2.Retail Pharmacies
8.3.Online Pharmacies

9MARKET INSIGHTS BY REGION

9.1NORTH AMERICA INJECTABLES ANTIDIABETIC DRUGS MARKET
- 9.1.1.U.S.
- 9.1.2.Canada
- 9.1.3.Rest of North America
9.2EUROPE INJECTABLES ANTIDIABETIC DRUGS MARKET
- 9.2.1.Germany
- 9.2.2.U.K.
- 9.2.3.France
- 9.2.4.Italy
- 9.2.5.Spain
- 9.2.6.Rest of Europe
9.3ASIA PACIFIC INJECTABLES ANTIDIABETIC DRUGS MARKET
- 9.3.1.China
- 9.3.2.Japan
- 9.3.3.India
- 9.3.4.Rest of Asia-Pacific
9.4REST OF THE WORLD INJECTABLES ANTIDIABETIC DRUGS MARKET